Lv41
420 积分 2024-10-17 加入
Safety study on adverse events of zanubrutinib based on WHO-VigiAccess and FAERS databases
1个月前
已完结
A Real‐World Study on Adverse Reactions of Belimumab Based on the FDA Adverse Event Reporting System Database
1个月前
已完结
Examining the safety of belimumab, especially in children: an analysis of real-world pharmacovigilance data from the US FDA adverse event reporting system (FAERS) database
1个月前
已完结
The risk of malignancy in patients with secukinumab‐treated psoriasis, psoriatic arthritis and ankylosing spondylitis: analysis of clinical trial and postmarketing surveillance data with up to five years of follow‐up
2个月前
已完结
Secukinumab long-term safety experience: A pooled analysis of 10 phase II and III clinical studies in patients with moderate to severe plaque psoriasis
2个月前
已完结
Clinical and histopathological characterization of eczematous eruptions occurring in course of anti IL-17 treatment: a case series and review of the literature
2个月前
已完结
Infection and infestation-related adverse events of biologics in psoriasis: insights from the food and drug administration adverse event reporting system (FAERS)
2个月前
已完结
Post-Marketing Safety Surveillance of Adalimumab, Secukinumab, and Infliximab in Hidradenitis Suppurativa: An Analysis of the FDA Adverse Events Reporting System (FAERS) Database
3个月前
已关闭
Infection and infestation-related adverse events of biologics in psoriasis: insights from the food and drug administration adverse event reporting system (FAERS)
3个月前
已完结
Novel anti-psoriasis agent-associated cardiotoxicity, analysis of the FDA adverse event reporting system (FAERS)
3个月前
已完结
皖公网安备34019202002308
